Wells Fargo raised the firm’s price target on McKesson (MCK) to $691 from $641 and keeps an Equal Weight rating on the shares. The firm’s 2025 adjusted EPS is unchanged, but Wells is increasing forward estimates on modestly stronger Pharma growth and more credit for annualizing Medical cost cuts. The firm cites modestly higher multiple, modestly higher core estimates, and including PRISM for the target change.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson’s Valuation Limits Upside Despite Positive Growth and Higher Price Target
- McKesson CEO Tyler sells $5.36M of shares
- McKesson designated a Bullish Fresh Pick at Baird
- McKesson’s Earnings Call Highlights Strong Growth
- McKesson, AmerisourceBergen succeed in dismissing claims, Bloomberg Law says